Skip to content

Sleep, Stress & Longevity

DSIP

Brain-derived peptide studied for deeper sleep, stress buffering and withdrawal; human sleep effects are modest and inconsistent.

RestrictedEvidence level 2 of 5: Animal data, minimal humanAlso: Delta Sleep-Inducing Peptide, Emideltide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu

Overview

DSIP was isolated in 1977 from the blood of rabbits in induced deep sleep, which gave it its name. Despite decades of research, its receptor and exact mechanism remain unclear. It appears to modulate several systems — GABA and glutamate signaling, the stress hormone axis, and circadian rhythm — and it crosses the blood–brain barrier unusually well for a peptide. Small early human studies suggested improved sleep continuity in some insomnia patients and reduced symptoms during opioid and alcohol withdrawal, but results were inconsistent and newer controlled trials are lacking. It appears very safe in available reports. Patients should know that DSIP cannot fix sleep apnea, poor sleep habits or other medical causes of insomnia.

Classification
Endogenous nonapeptide (9 aa), originally isolated from rabbit brain
Route
Subcutaneous; intranasal
Half-life
~7–15 minutes (very short)

Mechanism of action

Primary targetUndefined receptor; modulates GABAergic, glutamatergic and HPA pathways
  1. Blood–brain barrier passageCrosses into the brain relatively efficiently for a peptide.
  2. Neurotransmitter modulationEnhances GABA tone and dampens glutamate (NMDA) excitability.
  3. Stress axis bufferingLowers stress-driven ACTH and cortisol responses.
  4. Slow-wave sleep supportFavors delta-wave activity and sleep continuity in some studies.
Downstream effects
  • Improved sleep continuity
  • Blunted stress response
  • Withdrawal symptom relief

Researched for

  • Chronic insomnia
  • Narcolepsy
  • Opioid and alcohol withdrawal
  • Stress adaptation
  • Chronic pain

Research notes

  • Schoenenberger & Monnier (PNAS, 1977): isolation and sleep-promoting activity in rabbits.
  • Schneider-Helmert (1980s): small studies in chronic insomnia showed improved sleep efficiency in some patients; other trials were negative.
  • Dick et al. (1984) reported symptom relief in opioid and alcohol withdrawal in a small open study.
  • FDA's 2026 PCAC review weighed limited and inconsistent efficacy data; the committee narrowly voted against compounding eligibility.

Reported side effects

  • Drowsiness
  • Headache (rare)
  • Vivid dreams
  • Injection-site reactions

Contraindications & cautions

  • Untreated obstructive sleep apnea
  • Pregnancy and breastfeeding
  • Concurrent sedatives or alcohol without supervision
  • Corticosteroid therapy (theoretical HPA interaction)

Lab monitoring

  • CBC, CMP
  • AM and PM cortisol
  • Thyroid panel (TSH, free T4)
  • RBC magnesium
  • Sleep study if apnea suspected

Dosing and pricing for DSIP

Dosing references and compound pricing are available to established patients in the secure portal after a medical evaluation.

Ready to take control of your health?

Start with a 60-minute physician evaluation, virtually in seven states or in person in Reston, Virginia.

Request a consultation 703-400-5314

Cash-pay. HSA and FSA accepted. Monday–Friday, 10 AM – 2 PM (virtual and in person).